



Objective: To study the prevalence of Jaccoud arthropathy (JA) in a sample of local 
systemic lupus erythematosus (SLE) patients and its clinical and serological associa-
tions. Methods: 308 SLE patients from a single university center for the last two years 
were interviewed and examined. The presence of JA was searched for according to the 
JA index. After this, charts were reviewed for clinical and serological profile. Results: 
The studied sample was composed by 94.5% females and 5.5% males with mean age of 
38.08 ± 12.04 years and mean disease duration of 29.68 ± 11.63 years. A JA prevalence 
of 6.1% was found in this sample. There was a positive association of JA presence with 
arthritis complaints (p  =  0.001) and a negative association with renal involvement 
(p = 0.028). Patients with JA had higher positivity for anti-dsDNA (p = 0.022). Conclu-
sion: Despite the positive association of JA with arthritis and anti-dsDNA, there was a 
negative association with nephritis. This could suggest that JA patients belong with a SLE 
subset with a better prognosis. 
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RESUMO
Artropatia de Jaccoud em lúpus eritematoso sistêmico:  
achados clínicos e sorológicos 
Objetivo: Estudar as associações clínicas e laboratoriais da artropatia de Jaccoud (AJ) 
a partir de uma amostra de população local com lúpus eritematoso sistêmico (LES). 
Métodos: Realizou-se entrevista e exame físico em 308 pacientes com LES de um único 
hospital universitário acompanhados nos dois últimos anos para diagnosticar a presença 
de AJ de acordo com índice de AJ. Os prontuários foram revistos para o perfil clínico e 
laboratorial. Resultados: A amostra estudada compunha-se por 94,4% de mulheres e 
5,5% de homens com idade média de 38,08 ± 12,04 anos e duração média de doença de 
29,68 ± 11,63 anos. Encontrou-se uma prevalência de 6,1% de AJ. Foi observada uma as-
sociação positiva entre a presença de AJ e queixas de artrites (p = 0,001), bem como uma 
associação negativa com envolvimento renal (p = 0,028). Pacientes com AJ apresentaram 
uma maior positividade para o anticorpo anti-dsDNA (p = 0,022). Conclusão: A des-
peito de uma associação positiva com artrite e anticorpos anti-dsDNA pacientes com AJ 
têm menos nefrite. Isso pode apontar para um subtipo de LES com melhor prognóstico. 
Unitermos: Artrite; glomerulonefrite; lúpus eritematoso sistêmico.
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INTRODUCTION
Jaccoud arthropathy (JA) is a non-erosive deforming type 
of arthropathy first identified in patients with rheumatic 
fever in the 19th century by Dr. Jaccoud1, a French clini-
cian. Later, it was also described in systemic lupus ery-
thematosus (SLE) patients and in other diseases such as 
acquired immunodeficiency syndrome (AIDS), systemic 
sclerosis, dermatomyositis, hypocomplementemic vascu-
lites, and necrotizing vasculitides1-4. This form of arthrop-
athy causes severe deformities mainly in the hand joints 
with multiple subluxations; “swan neck” and “bouton-
niere” deformities in the fingers; “Z” distortion of thumbs; 
and ulnar drift of metacarpal-phalangeal joints, which can 
be easily misdiagnosed as rheumatoid arthritis5. Although 
most descriptions have focused on the hands, JA appears 
to be a generalized process that involves all capsular and 
periarticular tissues6. Unlike rheumatoid arthritis, all de-
formities in JA are reducible and usually cause little or no 
pain6. Joint function is rather well-preserved, and radio-
graphic studies do not show evidence of bone or cartilage 
damage. In rheumatoid arthritis, the loss of stability is due 
to hyperthrophic synovitis; in JA, the process involves 
mainly periarticular tissue and ligaments6. Although ar-
ticular involvement is one of the most common findings in 
lupus patients and frequently one of its initial manifesta-
tions7, JA is described in only 2% to 35% of cases8,9. SLE 
is a disease with a wide array of signs, symptoms, and au-
toantibody profile. It appears that some patients develop a 
particular subtype of disease where a cluster of clinical and 
serological findings are found, which can be useful in pre-
dicting the complete clinical picture. In the present study 
the prevalence of JA in a sample of SLE patients from this 
service was analyzed, searching for associated clinical and 
serological findings.
METHODS
This was an analytical and transversal study that was ap-
proved by the local committee of ethics in research, and all 
the participants signed an informed consent. All patients in-
cluded fulfilled at least four of the classification criteria from 
the American College of Rheumatology (ACR) for SLE di-
agnosis10. The 308 included patients represented a sample 
of 74.7% of patients with SLE diagnosis attended to at this 
clinic from July 2009 to July 2011. They were included con-
secutively according to appointment order and willingness 
to participate in the study. Patients were interviewed and ex-
amined to determine the presence of JA, according to the JA 
index9. The JA index determines the number and degree of 
deformities in hand joints on a scale from 0 to 14. The JA di-
agnosis was established when the index was equal to or over 
five and hand radiology studies were normal. All patients 
with arthritis complaints were submitted to a radiological 
study of the affected joints to exclude the presence of erosions. 
Patients’ charts were reviewed for presence of clinical 
findings that occurred during disease evolution and for 
serological profile. Clinical and autoantibody data were 
considered cumulatively and were obtained through chart 
review. Collected clinical data were considered as defined 
by the 1997 revised Classification Criteria of the ACR for 
SLE10. All patients with renal involvement (proteinuria over 
500 mg on two or more occasions) were submitted to renal 
biopsy according to local protocol except those who pre-
sented with class VI disease. Neuropsychiatric manifesta-
tions were identified according to the American College of 
Rheumatology nomenclature and case definition for neuro-
psychiatric lupus11. Data on Raynaud phenomenon, myosi-
tis, arthralgia, sicca symptoms, and hypothyroidism were 
also collected. Raynaud phenomenon was defined by dis-
coloration of fingers and/or toes induced by cold exposure 
or stress and observed by a doctor. Myositis was defined by 
proximal muscular weakness and rise in muscular enzymes 
in the absence of offending drugs or thyroid dysfunction; 
sicca symptoms were considered present if the patient had 
oral or ocular dryness not attributable to medications; ar-
thralgia was characterized by joint pain without signs of in-
flammation. Hypothyroidism was considered present when 
TSH was above 4.0 mU/L on at least two occasions12. The 
autoantibodies considered for analysis were: anti-Ro/SS-A, 
anti-La/SS-B, anti-RNP, anti-Sm, anti-dsDNA, anticar-
diolipin (aCl) IgG, aCl IgM, LA (lupus anticoagulant), di-
rect Coombs, and rheumatoid factor (RF). Anti-Ro/SS-A, 
anti-La/SS-B, anti-RNP, anti-Sm, aCl IgG, aCl IgM were 
tested by enzyme-linked immunoabsorbent assay (ELISA 
using ALKA and Orgentec Kits®); anti-dsDNA was tested 
by immunofluorescence technique (IFT) using Crithidia 
luciliae as a substrate. Lupus anticoagulant was exam-
ined through a screening test, the dilute Russell viper 
venom test (dRVVT) and confirmed by Russell Viper Ven-
om Time Test (RVVT). IgM rheumatoid factor was exam-
ined by latex agglutination test (BioSystems®). Data was 
collected in contingency and frequency tables. Fisher’s test 
and the chi-squared test were used for association studies 
of nominal data and unpaired t-test and Mann Whitney’s 
test were used for numeric data. Variables with p < 0.05 in 
the univariate analysis were submitted to analysis through 
a model of logistic regression to determinate the odds ratio 
(OR) and 95% confidence interval. Calculation was per-
formed with help of the software Graph Pad Prism version 
4.0 and Medcalc version 12.1.3.0. The adopted significance 
level was of 5%.
RESULTS
DESCRIPTION OF THE STUDIED SAMPLE
In the 308 SLE studied patients, the mean age was 38.08 
± 12.04 years (from 14 to 76 years) with median disease 
duration of 87 months (from 1 to 468 months). The gender 
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distribution showed 291/308 (94.5%) females and 17/308 
(5.5%) males. The mean age at diagnosis was 29.68 ± 11.63 
years (5 to 69 years). In this sample, 76.9% of the patients 
were using antimalarial drugs; 12.9%, methotrexate; 
2.59%, cyclophosphamide; 4.22%, mophetil mycopheno-
late; 15.58%, azathioprine; and 22.7%, steroids. The preva-
lence of clinical findings is seen in Table 1.
had anti-Ro; 55/290 (18.9%) had anti-La; 70/254 (27.4%) 
had anti-RNP; 64/292 (21.9%) had anti-Sm; 58/301 
(19.2%) had aCl IgG; 46/254 (18.1%) had aCl IgM; 40/275 
(14.5%) had a lupus anticoagulant; and 68/283 (24.02%) 
had rheumatoid factor.
ANALYSIS OF SLE POPULATION WITH JA IN COMPARISON TO 
THOSE WITHOUT JA
The study of the demographic data in relation to the pres-
ence of JA demonstrated that there were no differences in 
age, gender, or age at diagnosis. The median disease dura-
tion in those with JA was 84 months, and in those without 
it was 120 months (p = 0.08). Analysis of clinical data ac-
cording to the presence of JA showed that there was a sig-
nificant statistical difference in arthritis (present in 94.7% 
of JA patients versus 59.7% in those without it; p = 001) 
and kidney involvement (present in 15.78% of JA patients 
versus 59.7% in those without it; p = 0.028). All other clini-
cal variables, such as gender, median age, age at diagnosis, 
photosensitivity, malar rash, discoid lesions, oral ulcers, 
Raynaud phenomenon, arthralgia, myositis, pleural effu-
sion, pericarditis, psychosis, convulsions, hematologic dis-
orders, hypothyroidism, and sicca symptoms were equally 
distributed (p = ns). The serological profile in patients with 
and without JA demonstrated a statistically significant dif-
ference in anti-dsDNA antibodies prevalence, as can be 
seen in Table 2. 
  Number Percentage 
Photosensitivity 235/308 76.29%
Malar rash 153/298 51.34%
Discoid lesions 40/299 13.37%
Oral ulcers 134/298 44.96%
Raynaud phenomena 141/293 48.12%
Arthritis 189/305 61.96%
Migratory n = 59    19.34%
Additive   n = 130   42.62%
Arthralgia 47/305 15.40%
Myositis 10/308 3.24%
Pleural effusion 50/307 16.28%
Pericarditis 34/305 11.14%
Renal involvementa 122/299 40.8%
Class 6 n = 13  4.34%
Class 5 n = 25  8.36%
Class 4 n = 45      15.05%
Class 3 n = 24  8.02%
Class 2 n = 15   5.01%
Leukopeniab 91/303 30.03%
Lymphopeniac 47/296 15.87%




Hipothyroidism 59/ 287 20.55%
Sicca symptoms 66/288 22.91%
aAll proven by biopsy, except those in class 6; classiﬁcation according 
to ISN/RPS 200412; bLess than 4000/mm3 on at least two occasions, 
without use of immunosupressive drugs; cLess than 1500/mm3 on 
at least two occasions, without use of immunosupressive drugs; 
dLess than 100.000/mm3 on at least two occasions, without use of 
immunosupressive drugs; eIdentiﬁed according to the American 
College of Rheumatology’s nomenclature and case deﬁnition for 
neuropsychiatric lupus11.
Table 1 – Cumulative prevalence of clinical ﬁndings in 308 






Anti-dsDNA 13/19 - 68.4% 117/281 - 41.6%
Anti-Ro 8/19 - 42.1% 104/279 - 37.27%
Anti-La 2/18 - 11.1% 53/272 - 19.48%
Anti-Sm 5/18 - 27.7% 59/274 - 21.53%
Anti-RNP 5/17 - 29.4% 65/237 - 27.42%
aCl IgG 6/18 - 33.33% 52/283 - 18.37%
aCl IgM 3/15 - 20% 42/239 - 17.57%
LA 5/19 - 26.31% 35/256 - 13.67%
Coombs 0/17 17/238 - 7.14%
Rheumatoid factor 7/19 - 36.84% 61/264 - 23.10%
aCl, anticardiolipin; LA, lupus anticoagulant; JA, Jaccoud arthropa-
thy; DNA, deoxyribonucleic acid.
Table 2 – Comparison of serological data in 308 systemic 
lupus erythematosus patients according to the presence of 
Jaccoud arthropathy
All variables with p < 0.05 (renal disease, arthritis, and 
anti-dsDNA) were submitted to a logistic regression using 
Jaccoud arthropathy as the dependent variable. Arthritis 
and anti-dsDNA were found to influence the presence of 
Jaccoud arthropathy positively and renal disease nega-
tively. An OR = 10.06 (95% CI; 1.30-77.36) was found for 
In the studied population, 6.1% (19/308) of patients 
met the criteria for JA.
The serological profile of the studied sample showed 
that 130/300 (33.3%) had anti-dsDNA; 112/308 (36.3%) 
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arthritis; an OR = 2.93 (95% CI; 1.05-8.22) was found for 
anti-dsDNA, and an OR  =  0.22 (95% CI;0.06-0.81) was 
found for renal disease.
DISCUSSION
The pathogenetic factor that may cause certain SLE pa-
tients to develop JA is not yet clear. Some authors have as-
sociated JA with joint hypermobility, and others with hy-
perparathyroidism or with antiphospholipid syndrome6,7. 
van Vugt et al.6 found a relationship of JA and antiphos-
pholipid antibodies and suggested that small vessel throm-
bosis could cause ischemia and periarticular fibrosis. The 
study of the presence of joint hypermobility has controver-
sial results6,13,14. Hyperparathyroidism secondary to renal 
failure was considered a potential factor as it causes tendi-
nous laxity13. Another group of authors has linked JA to a 
persistent local inflammation9,14.  Bywaters15 proposed that 
constant joint inflammation in the synovial membrane and 
capsule causes fibrosis and capsule retraction, resulting in 
deformities. Although they are common, inflammatory 
reaction of joints in SLE are usually mild and transient. 
They tend to have more symptoms than objective signs, al-
though some patients may have a more persistent process. 
Spronk et al.9 found an association of JA with increased 
concentrations of C-reactive protein and suggested that 
this could be due to a persistent inflammatory reaction. 
According to these authors, infiltration of inflammatory 
cells in the articular tissues results in production of inter-
leukin (IL)-1 and IL-6, which may induce an acute phase 
reaction. A study with magnetic resonance imaging de-
tected capsular swelling and severe edematous tenosynovi-
tis in lupus patients with JA16. In the present study, arthritis 
complaints were more common in patients who developed 
JA, which favors this hypothesis. The present sample had a 
high prevalence of renal disease, as expected in a tertiary 
center. An interesting outcome of the present study was 
the negative relationship of JA with renal involvement, 
despite a positive association with anti-dsDNA. Although 
this may seem paradoxical, since this autoantibody has 
been considered a marker of renal disease12, the finding of 
a positive association with anti-dsDNA was also observed 
in two other studies8,17. Neither study noted any difference 
in the prevalence of renal involvement in patients with or 
without JA. Conversely,  a study by van Vugt et al.6 and 
another by Molina et al.18 detected a negative relation-
ship of JA with lupus nephritis, as the present study did. It 
should also be noted that in the present sample, all classes 
of renal involvement were present, and that the prevalence 
of positive anti-DNA may vary among them. As nephritis 
is a cause of high morbidity and even mortality in lupus 
patients, the presence of JA could indicate a subgroup of 
lupus patients with better prognosis. Another controver-
sial point in the literature concerns disease duration in 
patients with JA. While some authors have found that JA is 
more common in lupus patients with longer disease dura-
tion6,8, others such as Alarcón-Segovia et al.17, found that 
JA is more frequent in those with shorter duration. In the 
present study there was no difference in disease duration, 
but a trend towards a shorter disease in lupus patients with 
JA was noticed. In conclusion, in the studied sample JA 
was associated with clinically detected arthritis, with more 
anti-dsDNA and with less renal involvement. 
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